



Temsavir

Catalog No: tcsc0938

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 701213-36-7
Formula: C ₂₄ H ₂₃ N ₇ O ₄
Pathway: Anti-infection
Target: HIV
Purity / Grade: >98%
Solubility: DMSO : ≥ 16.67 mg/mL (35.21 mM)
Alternative Names: BMS-626529
Observed Molecular Weight: 473.48





Product Description

Temsavir (BMS-626529) is a novel attachment inhibitor that targets **HIV-1** gp120 and prevents its binding to CD4⁺ T cells.

IC50 & Target: HIV-1^[1]

In Vitro: Temsavir has half-maximal effective concentration (EC $_{50}$) values of 50 against LAI virus of 0.7±0.4 nM. Temsavir exhibits an EC $_{50}$ of 0.01 nM against the most susceptible virus and an EC $_{50}$ of >2,000 nM against the least susceptible virus. The cytotoxicity profile of Temsavir is examined in several cell types from different human tissues. CC $_{50}$ values of >200 μ M are observed in MT-2 (T lymphocytes), HEK293 (kidney), HEp-2 (larynx), HepG2 (liver), HeLa (cervix), HCT116 (colorectal), MCF-7 (breast), SK-N-MC (neuroepithelium), HOS (bone), H292 (lung), and MDBK (bovine kidney) cells measured after 3 or 6 days in culture. CC $_{50}$ values of 105 and 192 μ M are obtained in the T-cell line PM1 and in PBMCs, respectively, following 6 days in culture. These results show that Temsavir exhibits low cytotoxicity in cell culture^[1]. Temsavir exhibits a broad spectrum of antiviral activity against a panel of clinical isolates, with a 50% inhibitory concentration (IC $_{50}$) ranging from subnanomolar levels to >0.1 μ M^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!